
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed Inc. demonstrates a robust financial position with cash, cash equivalents, and marketable securities amounting to $38.9 million, indicating operational sustainability into mid-2026. The positive clinical data from the 16-week extension of the RewinD-LB Phase 2b trial for neflamapimod, which showcased statistically significant improvements in synaptic dysfunction symptoms, underlines the therapeutic potential of the company's lead candidate in treating age-related neurologic disorders. Additionally, the increase in R&D expenses reflects a committed investment in advancing clinical trials, strategically positioning CervoMed for future growth and development in the biotechnology sector.
Bears say
CervoMed Inc. faces significant financial risks due to its status as a clinical-stage biotechnology company with no current revenue-generating products and a history of operating losses since its inception. The company is subject to fierce market competition, which may hinder its ability to penetrate the market effectively or maintain suitable pricing for its product candidate, Neflamapimod. Additionally, delays in clinical development, regulatory approvals, and commercialization efforts could lead to increased costs and extended timelines, further complicating the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares